{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:39:06Z","timestamp":1791545946306,"version":"4.3.4"},"reference-count":30,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ipsen"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>This study aimed to assess the cost-effectiveness of abobotulinumtoxinA (aboBoNT-A) plus Best Supportive Care (BSC) compared with BSC alone for managing limb spasticity in adult patients in Greece, as well as to conduct a budget impact analysis of the introduction of aboBoNT-A in the Greek healthcare system compared to onabotulinumtoxinA (onaBoNT-A). Clinical studies were utilized to extract data on drug efficacy and patients\u2019 utility, while cost data were collected from Greek sources. The results of the study showed that aboBoNT-A plus BSC was a cost-effective treatment option for both upper and lower limb spasticity in adult patients compared to BSC. Additionally, introducing aboBoNT-A into the Greek healthcare system resulted in cost savings in pharmaceutical spending over a 5-year period. The findings suggest that incorporating aboBoNT-A into the Greek healthcare system could improve patient access to treatment and healthcare resource efficiency, as it is a more economical option compared to onaBoNT-A.<\/jats:p>","DOI":"10.3390\/toxins15090561","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T07:57:17Z","timestamp":1694159837000},"page":"561","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7871-4132","authenticated-orcid":false,"given":"Nikolaos","family":"Nomikos","sequence":"first","affiliation":[{"name":"Laboratory for Health Technology Assessment, Department of Public Health Policy, School of Public Health, University of West Attica, 11521 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Eleftheriou","sequence":"additional","affiliation":[{"name":"Ipsen Mepe, 17456 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Athanasakis","sequence":"additional","affiliation":[{"name":"Laboratory for Health Technology Assessment, Department of Public Health Policy, School of Public Health, University of West Attica, 11521 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4103\/1658-354X.121087","article-title":"Spasticity\u2014Pathogenesis, Prevention and Treatment Strategies","volume":"7","author":"Ghai","year":"2013","journal-title":"Saudi J. Anaesth."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00415-018-8759-1","article-title":"Defining Spasticity: A New Approach Considering Current Movement Disorders Terminology and Botulinum Toxin Therapy","volume":"265","author":"Dressler","year":"2018","journal-title":"J. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Nalysnyk, L., Papapetropoulos, S., Rotella, P., Simeone, J.C., Alter, K.E., and Esquenazi, A. (2013). OnabotulinumtoxinA Muscle Injection Patterns in Adult Spasticity: A Systematic Literature Review. BMC Neurol., 13.","DOI":"10.1186\/1471-2377-13-118"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2468","DOI":"10.1097\/MD.0000000000002468","article-title":"Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Lower Limb Spasticity","volume":"95","author":"Dashtipour","year":"2016","journal-title":"Medicine"},{"key":"ref_5","unstructured":"Royal College of Physicians of London, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy (Great Britain), and Association of Chartered Physiotherapists in Neurology (2008). Royal College of Occupational Therapists Spasticity in Adults: Management Using Botulinum Toxin: National Guidelines, Royal College of Physicians."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12955-015-0340-3","article-title":"The Negative Impact of Spasticity on the Health-Related Quality of Life of Stroke Survivors: A Longitudinal Cohort Study","volume":"13","author":"Gillard","year":"2015","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/NDT.S53913","article-title":"Epidemiological, Humanistic, and Economic Burden of Illness of Lower Limb Spasticity in Adults: A Systematic Review","volume":"10","author":"Abogunrin","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1016\/j.jval.2020.04.984","article-title":"PND92 Impact of Spasticity and of Waning of Effect of Botulinum Toxin A (Bont-A) Treatment on Patients\u2019 Employment and Quality of Life: Results of A Multinational Online Survey","volume":"23","author":"Esquenazi","year":"2020","journal-title":"Value Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"P5.6-019","DOI":"10.1212\/WNL.92.15_supplement.P5.6-019","article-title":"Burden of Spasticity among Patients and Caregivers: Results of a Multinational Survey (P5.6-019)","volume":"92","author":"Patel","year":"2019","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2147\/CIA.S91123","article-title":"Caregiver Burden, Productivity Loss, and Indirect Costs Associated with Caring for Patients with Poststroke Spasticity","volume":"1793","author":"Gillard","year":"2015","journal-title":"Clin. Interv. Aging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e17928","DOI":"10.2196\/17928","article-title":"Perspective of an International Online Patient and Caregiver Community on the Burden of Spasticity and Impact of Botulinum Neurotoxin Therapy: Survey Study","volume":"6","author":"Patel","year":"2020","journal-title":"JMIR Public Health Surveill."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/13696998.2021.1957582","article-title":"Comparative Efficacy, Safety, and Cost-Effectiveness of AbobotulinumtoxinA and OnabotulinumtoxinA in Children with Upper Limb Spasticity: A Systematic Literature Review, Indirect Treatment Comparison, and Economic Evaluation","volume":"24","author":"Danchenko","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4155\/cli.14.74","article-title":"AbobotulinumtoxinA for the Treatment of Upper Limb Spasticity","volume":"4","author":"Jost","year":"2014","journal-title":"Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1212\/WNL.0000000000004687","article-title":"Efficacy and Safety of AbobotulinumtoxinA in Spastic Lower Limb","volume":"89","author":"Gracies","year":"2017","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1474-4422(15)00216-1","article-title":"Safety and Efficacy of AbobotulinumtoxinA for Hemiparesis in Adults with Upper Limb Spasticity after Stroke or Traumatic Brain Injury: A Double-Blind Randomised Controlled Trial","volume":"14","author":"Gracies","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/j.jval.2021.04.797","article-title":"PND13 Cost-Effectiveness Analysis on Dysport: A Focus on Early Intervention to Improve Barefoot Walking Speed","volume":"24","author":"Moore","year":"2021","journal-title":"Value Health"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"A618","DOI":"10.1016\/j.jval.2017.08.1243","article-title":"The Cost Effectiveness of Abobotulinumtoxin A for Hemiparesis in Adults with Upper Limb Spasticity after Stroke or Traumatic Brain Injury in The United Kingdom\u2014A Bayesian Analysis","volume":"20","author":"Hansen","year":"2017","journal-title":"Value Health"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/ene.12062","article-title":"Cost-Effectiveness of OnabotulinumtoxinA for the Treatment of Wrist and Hand Disability Due to Upper-Limb Post-Stroke Spasticity in Scotland","volume":"20","author":"Doan","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"jrm00303","DOI":"10.2340\/jrm.v54.2422","article-title":"Modelling Long-Term Outcomes and Risk of Death for Patients with Post-Stroke Spasticity Receiving Abobotulinumtoxina Treatment and Rehabilitation Therapy","volume":"54","author":"Fheodoroff","year":"2022","journal-title":"J. Rehabil. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/13696998.2022.2092354","article-title":"The Cost-Effectiveness of AbobotulinumtoxinA (Dysport) and OnabotulinumtoxinA (Botox) for Managing Spasticity of the Upper and Lower Limbs, and Cervical Dystonia","volume":"25","author":"Danchenko","year":"2022","journal-title":"J. Med. Econ."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/CEOR.S76141","article-title":"Budget Impact Analysis of Botulinum Toxin A Therapy for Upper Limb Spasticity in the United Kingdom","volume":"7","author":"Abogunrin","year":"2015","journal-title":"Clin. Outcomes Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"A479","DOI":"10.1016\/j.jval.2014.08.1386","article-title":"Budget Impact Analysis of Botulinum Toxin A Therapy for Upper Limb Spasticity in Germany","volume":"17","author":"Zoellner","year":"2014","journal-title":"Value Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.pmrj.2017.06.007","article-title":"Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults with Upper Limb Spasticity Previously Treated with Botulinum Toxin: Subanalysis from a Phase 3 Randomized Controlled Trial","volume":"9","author":"Marciniak","year":"2017","journal-title":"PM&R"},{"key":"ref_24","unstructured":"NICE (2013). Guide to the Methods of Technology Appraisal 2013 Process and Methods."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Esquenazi, A., Gracies, J., Picaut, P., Grandoulier, A., and Delgado, M. (2019). AbobotulinumtoxinA Improves Functional Outcomes after Single and Repeat Dosing in Adults and Children with Spasticity [abstract]. PM&R, 11, Available online: https:\/\/pmrjabstracts.org\/abstract\/abobotulinumtoxina-improves-functional-outcomes-after-single-and-repeat-dosing-in-adults-and-children-with-spasticity\/.","DOI":"10.1016\/j.toxicon.2018.11.076"},{"key":"ref_26","unstructured":"(2023, June 01). National Organization for the Provision of Health Services (EOPYY) EOPYY Reimbursement List for Tests. Available online: https:\/\/eopyyfiles.blob.core.windows.net\/eopyysite\/ServiceCategories\/866f40c1-4d12-4f52-9cdc-f7f8dcbc1f70.pdf."},{"key":"ref_27","unstructured":"Hellenic Ministry of Finance, Hellenic Ministry of Labor, Social Insurance and Welfare, and Hellenic Ministry of Health (2023, June 05). Government Gazette Issue 946\/\u0392\/27.03.2012:Joint Ministerial Decision \u03a54\u03b1\/o\u03b9\u03ba.105494, Available online: https:\/\/www.google.com\/url?sa=i&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=0CDcQw7AJahcKEwigqO-N94iBAxUAAAAAHQAAAAAQAw&url=https%3A%2F%2Fwww.moh.gov.gr%2Farticles%2Fhealth%2Fdomes-kai-draseis-gia-thn-ygeia%2Fkwdikopoihseis%2Fkleista-enopoihmena-noshlia%2F1079-nea-lista-ken-apo-1-3-2012-kostos-mdn%3Ffdl%3D3769&psig=AOvVaw2UwyvYice_f0xVdQo2zgj_&ust=1693641153649958&opi=89978449."},{"key":"ref_28","unstructured":"Hellenic Ministry of Finance, Hellenic Ministry of Labor, Social Insurance and Welfare, and Hellenic Ministry of Health (2023, June 05). Government Gazette Issue 3096\/\u0392\/23.11.2012:Joint Ministerial Decision \u03a54\u03b1\/o\u03b9\u03ba.105494, Available online: http:\/\/www.et.gr\/idocs-nph\/search\/pdfViewerForm.html?args=5C7QrtC22wEbA_BZxkczbHdtvSoClrL8Hcsihn8f1EIfP1Rf9veiteJInJ48_97uHrMts-zFzeyCiBSQOpYnTy36MacmUFCx2ppFvBej56Mmc8Qdb8ZfRJqZnsIAdk8Lv_e6czmhEembNmZCMxLMtUp6gROBB3AeQKo8RTWTCbwwgxBtjpIVgh1q-uwg-7Fa."},{"key":"ref_29","unstructured":"Ministry of Health (2023, June 03). Official Medication Price Bulletin, Available online: https:\/\/Www.Moh.Gov.Gr\/Articles\/Times-Farmakwn\/Deltia-Timwn\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget Impact Analysis\u2014Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/9\/561\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:47:11Z","timestamp":1760129231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/9\/561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["toxins15090561"],"URL":"https:\/\/doi.org\/10.3390\/toxins15090561","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}